EUVIMEDEUVIMED entdecken
Übersichtsarbeit

NLRP3 Inflammasome Inhibitors as Precision Anti-inflammatory Pharmacotherapy: Translational Advances, Clinical Evidence, and Disease-specific Challenges

Md Farhan Raza, Alok Kumar, Hibah, Laiba Rizvi, Farheen Aftab, Mansi Devi, Sanchi Gupta, Sourabh Kosey

Inflammopharmacology · 2026-11 · 34 (11) · 6851-6863

DOI: 10.1007/s10787-026-02408-x ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Inflammopharmacology, online erschienen am 27.09.2026. Verfasst von Md Farhan Raza und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, ISF College of Pharmacy, Moga, Punjab, 142001, India. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes, Anti-Inflammatory Agents, Inflammation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome is pivotal ininnate immunity and inflammatory disease pathogenesis, notably through interleukins (IL)-1β and IL-18 and by triggering gasdermin D (GSDMD)-mediated pyroptosis. It has been implicated in cardiometabolic, renal, neuroinflammatory, and immune-mediated diseases, making NLRP3 a potential target for selective anti-inflammatory therapy. Clinical efficacy may vary according to disease biology, degree of NLRP3 inhibition, tissue distribution, and patient selection. This review covers the pharmacological and translational research of development of NLRP3 inhibitors and it summarizes the emerging clinical evidences from databases like PubMed, Scopus, Web of Science, Embase and ClinicalTrials.gov. It discusses several direct small-molecule NLRP3 inhibitors, including dapansutrile and selnoflastand others, including upstream activation mechanisms and downstream inflammatory mediators. Pharmacologic selectivity, potency, tissue distribution, activation of NLRP3 and clinical efficacy are among the key factors to consider in anti-inflammatory drug development. The success of these drugs in current use is variable, depending on the inflammatory type of the disease and the first generation of these drugs has shown liver toxicity. The role of the inflammasome in these conditions further supports the need for targeting NLRP3, especially in diseases such as cardiometabolic, renal and neuroinflammatory, but there are still hurdles to overcome, such as patient stratification and validation of biomarkers. Biomarker enriched populations should be targeted as a next step to improve the effectiveness of selective NLRP3 inhibition over current therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesAnti-Inflammatory AgentsInflammationHumansAnimalsTranslational Research, BiomedicalPrecision Medicine

Stichwörter der Autor:innen

Biomarker-guided therapyInflammasome-targeted therapyNLRP3 inflammasomeNLRP3 inhibitorsPrecision anti-inflammatory pharmacotherapyPyroptosis

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesAnti-Inflammatory AgentsNLRP3 protein, human

Autor:innen und Institutionen

  • Department of Pharmacy Practice, ISF College of Pharmacy, Moga, Punjab, 142001, India.
  • School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
  • Department of Pharmacy Practice, ISF College of Pharmacy, Moga, Punjab, 142001, India. sanchigupta1353@gmail.com.
  • Department of Pharmacy Practice, ISF College of Pharmacy, Moga, Punjab, 142001, India. sourabhkosey@gmail.com.

Zitieren

APA

Raza, M. F., Kumar, A., Hibah, Rizvi, L., Aftab, F., Devi, M., Gupta, S., & Kosey, S. (2026). NLRP3 Inflammasome Inhibitors as Precision Anti-inflammatory Pharmacotherapy: Translational Advances, Clinical Evidence, and Disease-specific Challenges. Inflammopharmacology, 34(11), 6851-6863. https://doi.org/10.1007/s10787-026-02408-x

Vancouver

Raza MF, Kumar A, Hibah, Rizvi L, Aftab F, Devi M, et al. NLRP3 Inflammasome Inhibitors as Precision Anti-inflammatory Pharmacotherapy: Translational Advances, Clinical Evidence, and Disease-specific Challenges. Inflammopharmacology. 2026;34(11):6851-6863. doi:10.1007/s10787-026-02408-x

BibTeX
@article{Raza2026,
  author = {Raza, Md Farhan and Kumar, Alok and Hibah and Rizvi, Laiba and Aftab, Farheen and Devi, Mansi and Gupta, Sanchi and Kosey, Sourabh},
  title = {NLRP3 Inflammasome Inhibitors as Precision Anti-inflammatory Pharmacotherapy: Translational Advances, Clinical Evidence, and Disease-specific Challenges},
  journal = {Inflammopharmacology},
  year = {2026},
  volume = {34},
  number = {11},
  pages = {6851--6863},
  doi = {10.1007/s10787-026-02408-x}
}
Kostenlos starten →